阿斯利康全球执行副总裁贝旭鸿：中国已成为全球创新药物枢纽

Core Insights - AstraZeneca announced a $2.5 billion investment in Beijing, which includes establishing a sixth global strategic R&D center and an advanced AI and data science laboratory, highlighting China's role as a global hub for innovative drug development [2] - The number of drugs developed in China has doubled, with approximately one-third of global licensing deals involving Chinese biopharmaceutical companies, indicating China's emergence as a source of innovation [2] - AstraZeneca aims to collaborate with promising Chinese biotech firms to achieve its goal of introducing 20 breakthrough innovative drugs globally by 2030 [2] - In the past two years, AstraZeneca has signed 15 licensing agreements with 14 Chinese biotech companies, showcasing its commitment to leveraging local innovation [2] - AstraZeneca plans to establish around 800 diagnostic and treatment centers in China by the end of 2025 to enhance standardized treatment across various disease areas [3] Company Strategy - AstraZeneca's investment in China is driven by the country's rich clinical research resources and improving innovation capabilities, positioning it as a key hub for global research and clinical development [3] - The company is focused on integrating into China's life sciences ecosystem and is actively seeking collaborations with companies that align with its product portfolio [2] Future Outlook - AstraZeneca is optimistic about the potential for increased foundational research collaboration and innovative therapy exploration in China, aiming to inject stronger momentum into global drug development [3]